Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Ave, Boston, MA, 02115, USA.
J Mol Med (Berl). 2018 Jan;96(1):1-8. doi: 10.1007/s00109-017-1560-2. Epub 2017 Jun 23.
Visualizing post-translational modifications, conformations, and interaction surfaces of protein structures at atomic resolution underpins the development of novel therapeutics to combat disease. As computational resources expand, in silico calculations coupled with experimentally derived structures and functional assays have led to an explosion in structure-based drug design (SBDD) with several compounds in clinical trials. It is increasingly clear that "hidden" transition-state structures along activation trajectories can be harnessed to develop novel classes of allosteric inhibitors. The goal of this mini-review is to empower the clinical researcher with a general knowledge of the strengths and weaknesses of nuclear magnetic resonance (NMR) spectroscopy in molecular medicine. Although NMR can determine protein structures at atomic resolution, its unrivaled strength lies in sensing subtle changes in a nuclei's chemical environment as a result of intrinsic conformational dynamics, solution conditions, and binding interactions. These can be recorded at atomic resolution, without explicit structure determination, and then incorporated with static structures or molecular dynamics simulations to produce a complete biological picture.
在原子分辨率下可视化蛋白质结构的翻译后修饰、构象和相互作用表面,是开发新型治疗药物以对抗疾病的基础。随着计算资源的扩展,计算与实验衍生的结构和功能测定相结合,导致基于结构的药物设计(SBDD)呈爆炸式增长,有几种化合物正在临床试验中。越来越明显的是,可以利用“隐藏”的激活轨迹中的过渡态结构来开发新型变构抑制剂。本综述的目的是使临床研究人员对磁共振(NMR)光谱在分子医学中的优势和局限性有一个总体的了解。尽管 NMR 可以在原子分辨率下确定蛋白质结构,但它无与伦比的优势在于能够感应由于固有构象动力学、溶液条件和结合相互作用而导致核化学环境的细微变化。这些可以在没有明确结构确定的情况下以原子分辨率记录下来,然后与静态结构或分子动力学模拟相结合,以产生完整的生物学图像。